Pasithea Therapeutics(NASDAQ) KTTAW

Market CapN/A

Since IPO (2021)-99%

5 YearN/A

1 Year-63%

1 Month+14%

$0.01

-2.7%

-0.00Today

Pasithea Therapeutics last closing stock price
Metric	Price	Date
Last close	USD 0.01	2026-07-27

Pasithea Therapeutics stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-23.47%	USD 0.01	2026-07-20
1 month	+13.64%	USD 0.01	2026-06-24
3 month	+24.98%	USD 0.01	2026-04-28
Year to date	-46.81%	USD 0.01	2025-12-31
1 year	-62.87%	USD 0.02	2025-07-23
3 year	-88.55%	USD 0.07	2023-07-28
Since inception	-99.14%	USD 0.87	2021-09-15

Pasithea Therapeutics Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$0.00

Net Income (TTM)

-$19.73M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.01

Volume

Open

$0.01

Price

$0.01

Volume

Open

$0.01

Previous Close

$0.01

Daily Range

$0.01 - $0.01

52-Week Range

$0.00 - $0.12

Estimated Earnings Date

Jun 3, 2026

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.01

Volume

Open

$0.01

Previous Close

$0.01

Daily Range

$0.01 - $0.01

52-Week Range

$0.00 - $0.12

Estimated Earnings Date

Jun 3, 2026

KTTAW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Pasithea Therapeutics

Pasithea Therapeutics Corp. is a biotechnology firm focused on developing innovative therapies for psychiatric and neurological conditions. The company aims to establish specialized clinics for depression treatment, utilizing intravenous ketamine infusions administered by certified pharmacists.

Products and Services

Development of therapies for psychiatric and neurological disorders
Establishment of clinics for depression treatment
Business support services for clinic operations

Growth Outlook

Significant market potential in the mental health sector
Plans to expand clinic network across multiple locations
Focus on innovative treatment methods to address unmet needs

Financial Highlights

Cash and cash equivalents of $50.4 million as of March 31, 2026
Current ratio of 35.4 indicates strong liquidity position
Net income of -$2.87 million for Q1 2026, reflecting ongoing investment in R&D

Pasithea Therapeutics Corp. is positioned in a growing industry with a focus on addressing significant mental health challenges. The company's strategy includes not only the development of innovative therapies but also the establishment of clinics to provide direct patient care. With a robust cash position and a strong current ratio, the company is well-equipped to pursue its growth initiatives. The ongoing investment in research and development underscores the commitment to creating effective treatment options for patients suffering from psychiatric and neurological conditions.

AI Generated • Jul 16, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

Miami Beach, FL 33139, US

KTTAW Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-57.44%

Return on Capital

-37.77%

Return on Assets

-35.02%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

Volume

Avg. Volume

10.08K

Financials (TTM)

Gross Profit

-$315.50K

Operating Income

-$22.05M

EBITDA

-$21.40M

Operating Cash Flow

-$16.94M

Capital Expenditure

$3.00

Free Cash Flow

-$16.94M

Cash & ST Invst.

$50.40M

Total Debt

$0.00

Pasithea Therapeutics Performance Analysis

Pasithea Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	N/A
Q3	2025-09-30	N/A
Q4	2025-12-31	N/A
Q1	2026-03-31	N/A

Pasithea Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	79.7%
Q3	2025-09-30	37.9%
Q4	2025-12-31	-117.1%
Q1	2026-03-31	53.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$157.54K

N/A

Gross Margin

0.00%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

N/A

Net Income

-$2.87M

+19.5%

EBITDA

-$4.72M

-34.1%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$50.40M

+843.6%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-35.02%

N/A

Return on Invested Capital

-40.20%

N/A

Free Cash Flow

-$4.79M

-56.7%

Operating Cash Flow

-$4.79M

-56.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

COEPCoeptis Therapeutics Holdings, Inc.

COEPCoeptis Therapeutics Holdings, Inc.$10.99-8.57%

NKGNNKGen Biotech, Inc. Common Stock

NKGNNKGen Biotech, Inc. Common Stock$0.06+0.00%

SYRSSyros Pharmaceuticals, Inc.

SYRSSyros Pharmaceuticals, Inc.$0.00+0.00%

VRPXVirpax Pharmaceuticals, Inc.

VRPXVirpax Pharmaceuticals, Inc.$0.00-75.00%

MSPRMSP Recovery, Inc.

MSPRMSP Recovery, Inc.$0.00+0.00%

SLXNWSilexion Therapeutics Ltd.

SLXNWSilexion Therapeutics Ltd.$0.04-13.33%

REVBRevelation Biosciences, Inc.

REVBRevelation Biosciences, Inc.$1.06+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

INTCIntel

INTCIntel$91.67-0.01%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.25+0.10%

NOKNokia

NOKNokia$9.28+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.95+0.03%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.24-0.02%

TAT&T

TAT&T$24.42+0.01%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$63.40-0.01%

Questions About KTTAW

What is the current price of Pasithea Therapeutics?

Pasithea Therapeutics is trading at $0.01 per share.

What is the 52-week range for Pasithea Therapeutics?

Over the past 52 weeks, Pasithea Therapeutics has traded between $0.00 and $0.12.

How much debt does Pasithea Therapeutics have?

Pasithea Therapeutics total debt is unavailable.

How much cash does Pasithea Therapeutics have on hand?

Pasithea Therapeutics does not have cash on hand data available.

What is Pasithea Therapeutics’s dividend yield?

Pasithea Therapeutics does not currently have a dividend yield.

Pasithea Therapeutics(NASDAQ) KTTAW

Pasithea Therapeutics Financials at a Glance

KTTAW News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Pasithea Therapeutics

KTTAW Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Pasithea Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About KTTAW

What is the current price of Pasithea Therapeutics?

What is the 52-week range for Pasithea Therapeutics?

How much debt does Pasithea Therapeutics have?

How much cash does Pasithea Therapeutics have on hand?

What is Pasithea Therapeutics’s dividend yield?

Premium Investing Services